Assessment of the quality of granulocyte concentrates to optimise their use in transfusion therapy
White blood cells known as granulocytes play a key role in protecting our bodies against infection. The most abundant granulocyte in circulation, the neutrophil, is an expert in ingesting and destroying bacteria and fungi. Our survival depends on these cells as their absence is not compatible with life. Patients with neutrophil deficiencies are highly vulnerable to infections. These life threatening situations are treated with antibiotic and anti-fungal drugs. Some patients require, however, further medical intervention. These patients can be treated with granulocyte transfusions to protect them until their bodies produce a sufficient number of neutrophils. There is only one source of granulocytes in Canada, those prepared by Héma-Québec who ships them across the country. Quality control of these granulocyte preparations is based mostly on the numbers of granulocytes. The quantity of granulocytes does not, however, reflect the functional capacity of these cells. The objective of this project is to assess the viability and functional capacity of granulocytes used for transfusions using well-established cell biology techniques. Impact: The results of this research will contribute to improving the quality control and by extension the safety and efficacy of granulocyte concentrates used to treat Canadian patients with life threatening conditions.
Principal Investigator / SupervisorFERNANDES, Maria
Co-Investigator(s) / TraineeGIRARD, Mélissa BRANCH, Donald
ProgramBlood Efficiency Accelerator Program
Total Amount Awarded$30,000
Project Start Date
Project End Date